The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.

After the latest funding and merger, OnKure will have enough resources to support operations into Q4 2026, including development of its PI3Kα inhibitors.

The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.

NEW YORK – AstraZeneca on Monday said it has inked an exclusive license agreement with Shijiazhuang, China-based CSPC Pharmaceutical Group to develop an early-stage small molecule lipoprotein(a) ...

Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and ...

The decision reaffirming the FDA's oversight authority over cell and gene therapy products was praised by the International ...

Patients had fewer bleeds after treatment with Beqvez compared to standard treatment, but questions remain about which ...

The radiopharmaceutical, already approved for SSRT-expressing GEP-NETs, may be a new option in meningioma if future research ...

Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...

NEW YORK – Avistone Biotechnology said on Friday that it will begin studying its c-MET inhibitor ANS01 in a Canada-based Phase I trial enrolling patients with MET-altered solid tumors. The ...